Clinical trialNCT03943004RecruitingPhase 1Interventional

Trial of DFP-14927 in Advanced Solid Tumors

SponsorDelta-Fly Pharma, Inc.Enrollment30CancerSolid Tumor

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Jaffer Ajani, MD
M.D. Anderson Cancer Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Ucla Department of Medicine- Hematology/oncology
Los Angeles, California, United States
Zev Wainberg, MD
Recruiting
Md Anderson Cancer Center
Houston, Texas, United States
Jaffer Ajani, M.D.
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

DFP-14927

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Sept 2019
Primary completion: 1 Mar 2026
Completion: 1 Jun 2026
Last update posted: 3 Mar 2025
Registered enrollment: 30
Registry id: NCT03943004

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.